Science, strategy and partnerships for the veterinary vaccine sector

9-11 November 2015
Silken Puerta América, Madrid
Science, strategy and
partnerships for the
veterinary vaccine sector
Created by
Co-located with
terrapinn.com/WVVC
Part of
THE WORLD VETERINARY VACCINE
CONGRESS 2015 IS…
The World Veterinary Vaccine Congress is a two day event with a pre-event workshop
where the global animal health industry meets to discuss scientific, regulatory and
commercial issues from new innovative vaccine technologies to emerging disease.
NEW VACCINE TECHNOLOGY AND PLATFORMS
Focused on R&D innovations, this congress will update you of the progression made in
veterinary vaccine R&D and vaccine development challenges when developing vaccines against
viral, bacterial and parasitic diseases within a variety of animal species. From modified live virus
vaccines, DNA vaccines, subunit marker vaccines to novel adjuvanted vaccines, this congress
brings all innovation together in one place.
INDUSTRY INSIGHTS AND MARKET TRENDS
Bridge the gap between animal and human health with a one health approach to control
emerging diseases in a changing world. Hear from regulators who can advise you on what they
are looking for when assessing new platforms for registration. DEVELOPING AND FORMULATING NEW VACCINES
From novel combination adjuvants for veterinary vaccines to making vaccines more affordable,
meet experts who can delve into process improvements approaches when developing new
vaccines.
ANTIMICROBIAL RESISTANCE AND EMERGING DISEASES
Expect the unexpected, explore the opportunities and challenges associated with emerging
infectious diseases including African swine fever, avian influenza and Rift Valley Fever. Find out
how the industry is working together to find alternative routes (vaccines) to slow down the rise of
antimicrobial resistance.
PRE-CONGRESS WORKSHOP: FROM AGENT IDENTIFICATION TO VACCINE SUPPLY
Find out how to tackle the problems associated with identification of new threats and the
turnaround time to producing vaccines. Discuss how the industry can readjust the risk
assessment when responding to a new outbreak.
Want to get involved? Contact Wing-yun Cheung on +44 (0)20 7092 1172 or wing-yun.cheung@terrapinn.com
2
“It was a great meeting with the right size. High level of executives
attending, with quality presentations.”
Vice President, Global Biologics Research, Zoetis, 2014 World Veterinary
Vaccines Congress Washington delegate
WHY ATTEND?
1
Meet high level speakers from big pharma and biotechs including Rodolfo
Bellinzoni, COO, Biogenesis Bagó and Dr Konrad Stadler, Boehringer
Ingelheim. Arrange your 1-2-1 meetings with MSD Animal Health, Ceva, Merial,
Biogenesis Bagó, Boehringer Ingelheim Animal Health, VEROVACCiNES and
Bioaster who could progress your projects and offer opportunities for collaboration
2
Hear from leading academics from Albert Osterhaus to Bryan Charleston, to
institutions and regulatory bodies including Erasmus MC, the Bill and Melinda
Gates Foundation, VIDO-InterVac, Veterinary Medicines Directorate, GALVmed,
IBET and many more.
3
Attend focused sessions covering new vaccine technology, vaccine formulation,
emerging and re-emerging diseases as well anti-microbial resistance. Gain regulatory
perspective from both the VMD and industry while learning how the European
Commission can help fund your projects to progress even further.
4
Connect with your peers in an interactive pre-congress workshop to find out
how to tackle the problems associated with the identification of new threats and the
turnaround time to producing vaccines.
5
Brainstorm how best to prepare for and prevent pandemics in avian influenza and
emerging diseases in a modern, globalised world.
6
Explore technologies to improve vaccine development, use of adjuvants and delivery
routes for better immunity and vaccine uptake.
7
Unparalleled networking opportunities, with over two days worth of content, extended
breaks and drinks reception with the 16th World Vaccine Congress, book now to
build partnerships to accelerate your vaccine pipeline with over 300 total attendees.
Register now at terrapinn.com/bookvetvacc
4
PRE-CONGRESS WORKSHOP 9 NOVEMBER 2015
DAY 1 10 NOVEMBER 2015
FROM AGENT IDENTIFICATION TO VACCINE SUPPLY: PROBLEMS ASSOCIATED WITH IDENTIFICATION
OF NEW THREATS AND THE TURNAROUND TIME TO PRODUCING VACCINES
14:45
16:15
16:45
• How can we shorten the time to introduce a new vaccine in response to an outbreak?
Dr Samuel Thevasagayam, Deputy Director, Agriculture Development Livestock, Bill and Melinda Gates Foundation
• The need to readjust risk-assessment of new outbreaks
12:50
• Why do we need GMOs to control new threats? How do we overcome (irrational) fear for GMOs?
14:20
Jeroen Kortekaas, Virologist/Project Leader, Central Veterinary Institute of Wageningen University Research
Progression in veterinary vaccine R&D: Challenges in developing new vaccine technologies
• Research into novel vaccine technologies
Dr Bryan Charleston, Acting Director of Science, The Pirbright Institute
14:50
See website for most up-to-date agenda
Networking Lunch
• Developing commercial veterinary vaccines against viral, bacterial and parasitic diseases within a variety of
animal species
Summary and end of workshop
1 OF 2
Chair’s opening remarks
15:20
• Antibiotic and antiviral resistance: Medical vs. veterinary drivers
• Novel technologies, biodiversity and emerging pathogens
Prof Albert Osterhaus, Professor and Head of the Department of Virology, Erasmus MC
• Improving and developing (vectored) vaccines against human and animal pathogens
• Using VZV, EHV-1 and MDV BACs to develop modified live and DNA vaccines
• Interaction between the human varicella zoster virus (VZV) as well as the animal herpesviruses equine herpesvirus
type 1 (EHV-1) and Marek’s disease virus (MDV)
Prof Klaus Osterrieder, Managing Director, Institute of Virology, Department of Veterinary Medicine, Freie Universität Berlin
A new antibiotic-free DNA vaccine system/technology
• Applying an effective vaccine platform successfully in allergy, cancer vaccines to animal health
• Engaging a powerful immune response
Dr Edmond Jolivet, Head of Molecular Bacteriology laboratory, Merial
One health: Controlling emerging diseases in a changing world
• Pathogens and predisposing factors at the human-animal interface
Modified live virus vaccines using a novel vector
• Harnessing the natural power to directly traffic antigens to antigen presenting dendritic cells REGULATORY PERSPECTIVES, INDUSTRY INSIGHTS AND MARKET TRENDS OF ANIMAL VACCINES
09:05
• The need, benefits and challenges
• Partnering for sustainable access to quality veterinary vaccines, medicines and diagnostics
17:45
09:00
Controlling livestock diseases in the developing world to realise increased productivity and value
• Technologies in vaccines & diagnostics, genetic approaches and management
Networking Break
DAY 1 10 NOVEMBER 2015
2 OF 2
NEW VACCINE TECHNOLOGY AND PLATFORMS
12:20
• Prime example: Rift Valley Fever and Schmallenberg
See website for most up-to-date agenda
15:50
16:20
Afternoon Break
Development of Immunological reagents and assays for the veterinary field
• Specific monoclonal antibodies for veterinary immunology research in vaccine development
• Monoclonal antibody-based ELISA and ELISpot for measuring IFN-y and other cytokines in several species
09:35
Bridging the gap between animal and human adjuvanted vaccines
• ELISpot/FluoroSpot: defining vaccine efficiency by measuring T-cell response at the single cell level
• How can we extrapolate the use of adjuvants in animal and human vaccines to benefit all species
Dr Eva Geliu, Team Leader R&D, Mabtech AB
• Measuring efficacy, toxicity and correlates of protection
Dr Nathalie Garcon, CSO/CTO, Bioaster
10:05
16:35
The EC perspective with regards to vaccine research From FP6 to Horizon 2020
• Overview of the EU Framework Programme for research funding “Horizon 2020” and work programming • Overview of animal Health research in FP6 & FP7 with a focus on vaccinology
16:50
• Presentation of most recent initiatives on animal health, in particular on vaccinology
Jean-Charles Cavitte, Planning and Programming Officer, Research & Innovation, European Commission DG
Agriculture and Rural development Unit
10:35
Networking Break
11:20
Overcoming regulatory challenges in evaluating new technology and self-derived platforms
for registration
• What are regulatory bodies looking for when assessing new platforms for registration?
11:50
What is changing in vaccination? Implementation of new technologies
• Easing vaccine development processes and combining vaccines
• Overcoming compatibility hurdles in vaccines
• Vaccine application, vaccine development, vaccine presentation - Prof Manuel Carrondo, Director & Lab Head, IBET
• Addressing equipment needs, freeze drying techniques and molecular technology
Dr Rik Koopman, Global Technical Director, MSD Animal Health
EXPLORING MULTIPLE DELIVERY ROUTES
17:20
Novel aspects of subunit marker vaccines for animal health
• Using a yeast technology approach that uses single viral components for immunisation
• Addressing common regulatory pitfalls in the commercialisation of new technologies
• Creating a high safety standard and an easy, low cost vaccine that can be applicable to nearly all pathogens
Dr Noemi Garcia del Blanco, Head of Biologicals Assessment Team, Veterinary Medicines Directorate
• Shortening response time for emerging viral threats
Dr Hanjo Hennemann, Head of R&D, VEROVACCiNES
Global regulatory strategy for veterinary medicines and vaccines
• Understanding the different global demands and limitations for your vaccine product: The different registration routes in each market
• How do the current concerns about increasing resistance to the antimicrobials used in human and animal health affect vaccine
development?
17:50
• Preparing for the safety considerations when developing your product
Dr Jacques Léchenet, Head of Regulatory Biological New Projects, Merial
5
Live recombinant veterinary vaccines: Cancer vaccine strategies and mechanisms of action • Selectively engineering protective determinants used for antigens
• Re-designing and simplifying vaccine combinations
• Leveraging new understanding of pathogens to develop cross-protective vaccines
18:20
Modified replication-deficient viruses as a delivery vector
• Overview and advantages of vaccine delivery platform technology
• Current and past animal vaccine development efforts
• Future directions and potential hurdles
Chair’s closing remarks and Networking Drinks Reception
6
DAY 2 11 NOVEMBER 2015
09:15
See website for most up-to-date agenda
Chair’s opening remarks
CO-LOCATED WITH
DEVELOPING AND FORMULATING NEW VACCINES
09:20
Making vaccines more affordable, using process improvements to East Coast Fever vaccine
as an example
• The need for closer collaboration between animal and human health
• Recognising that one health is a major component of food security, safety, human, animal and environmental health
• Controlling the rise of anti-microbial resistance and livestock diseases reaching new boarders
Dr Jeremy Salt, Senior R&D Director, GALVmed
09:50
Viral vectors in animal health and future applications
• Opportunities in implementing high technology vector vaccine research
• Lesson learned in vector vaccine development – how will this change the future landscape?
Dr Konrad Stadler, Head of R&D Vaccines, Boehringer Ingelheim
10:20
Novel combination adjuvants for veterinary vaccines
• New combination of adjuvants which give immunity to many neonates species
• Producing vaccines that are long lasting and applicable to pertusis, RSV and veterinary models
• Developing adjuvant testing and design, providing evidence through assays and delivery system
Prof Volker Gerdts, Assoc Director, VIDO, Saskatoon, Saskatchewan
10:50
• Successfully increasing vaccine thermal stability
Professor Manuel Carrondo, Director & Lab Head, IBET
Evaluating the threat of new and emerging avian influenza stains: How is the industry
addressing this problem?
• Evaluating the situation of the disease and the current approach to reduce the losses associated to it
• What are the new perspectives in terms of vaccine development?
Dr Marcelo Paniago, Director Global Veterinary Services Poultry, Ceva Santé Animale
12:30
Vaccine options for the intercontinental H5NX highly pathogenic avian influenza
• DIVA vaccine - vectored vaccines
• Live attenuated vaccine: species specific vaccines
• Universal vaccine
13:00
14:00
14:30
15:00
7
EVEN MORE EXECUTIVE LEVEL BIG PHARMA AND BIOTECH
With over 40 senior representatives from big pharma and biotechs in the speaker faculty alone, we can
guarantee you will have more opportunities to learn from and network with these key stakeholders. Meet
CSOs and VPs from
and many more.
Testing a new formulation for Peste des Petits Ruminants vaccine in Ethiopia
• Procuring vaccines against neglected veterinary diseases to African vaccine producing laboratories
12:00
RESEARCH, DEVELOPMENT AND STRATEGIC PARTNERING FOR THE
VACCINE INDUSTRY
Morning networking break
ANTIMICROBIAL RESISTANCE AND EMERGING & RE-EMERGING DISEASES
11:30
16th Annual
HEAR FROM EXPERT ACADEMIC AND REGULATORY INDIVIDUALS FROM LEADING
INSTITUTIONS
From Dr Gregory Poland to Adrian Hill, learn how the Mayo Clinic, Jenner Institute, Institut Pasteur,
Erasmus MC, AIFA, Statens Serum Institut, IBET, PHE, Fraunhofer US, Paul Ehrlich Institute and
many more are researching to create innovative new vaccines.
EVEN MORE COVERAGE THROUGH MULTIPLE TRACKS TO ENSURE THREE DAYS OF
RELEVANT CONTENT
Multiple tracks covering more topics throughout the three days will ensure every day is tailored to your needs.
Track topics include respiratory vaccines, therapeutic vaccines, emerging & re-emerging diseases, new
vaccine technology, pre-clinical validation, clinical trials, bioprocessing, delivery and manufacture.
Professor Chang-Won Lee, Department of Veterinary Preventive Medicine, The Ohio State University
PANEL SESSIONS WILL ALLOW YOU TO QUESTION EXPERTS ON KEY TOPICS
Networking lunch
Quiz our speakers on sessions that include: How to build a vaccine around an emerging disease model, fast
track approaches to clinical trials in absence of Phase III efficacy results, and where is big pharma going in
the coming year?
Intervention strategies to support the global control and eradication of foot-and-mouth disease virus
• Foot and mouth disease (FMD), one of the costliest animal disease affecting trade of animals and animal products
throughout the world
• Maintaining a high level of surveillance and response against FMD virus incursions
• Intervention strategies through vaccination
• Production of new generation vaccines to overcome challenges in vaccine development due to diversity of the
virus, lack of temperature stability and short duration of immunity
Rodolfo Bellinzoni, COO, Biogenesis Bagó
THERE ARE MORE NETWORKING OPPORTUNITIES
With three days worth of content, extended breaks and two drinks receptions, you will have even more time
to meet contacts who will progress your projects and offer opportunities for collaboration.
Anti-microbial resistance challenges for policy makers and scientists
• How to avoid a post-antibiotic era, in which common infections and minor injuries can once again kill
• Working together with industry to find alternative routes (vaccines) to slow down the rise of resistance
Chair’s closing remarks and close of congress
Want to get involved? Contact Wing-yun Cheung on +44 (0)20 7092 1172 or wing-yun.cheung@terrapinn.com
8
GET YOUR
ORGANISATION NOTICED
7
8
9
6
10
10
5
11
11
Why sponsor?
•
•
•
•
•
20 19
19
20
Debut new products
Raise the profile of your brand
Meet new business partners and suppliers
Develop key relationships
Educate pharma and biotech companies
21 18
18
21
3
• Make sales
22
22
Who will you meet?
•
•
•
•
•
•
•
•
112
Pharma
SME Biotech
Decision-makers
Influencers
Government Bodies
Regulatory Boards
Academic and Research Institutes
Venture Capital
113
17
17
114
23 16
16
23
22
11
115
BOOKED
• Industry Solution Providers
AVAILABLE
This is a superb opportunity for:
•
•
•
•
•
CROs
CMOs
Pharma
Biotech
Platform Technology Providers
• OEM / Equipment Providers
Sponsorship opportunities include:
•
•
•
•
•
•
Programme presence
Exhibition
Drinks Reception Sponsor
Poster Session Sponsor
Networking Break Sponsor
Lanyard Sponsor
• Wi-Fi Sponsor
And many more…
9
RESERVED
* Last updated 13 May 2015. See website for most up-to-date version.
CONFIRMED EXHIBITORS
COMPANY
BUFFET
SPONSORS & EXHIBITORS
BOOTH NO.
COMPANY
BOOTH NO.
3M
16
Luminex
6
4 Clinics
19
Pantec Biosolutions
21
Accelovance
10
Quintiles
3
Batavia BioSciences
8
hVIVO
15
BioKinetic Europe
23
Teleflex Medical
22
ExpreS2ion Biotechnology
12
Virocyt / I&L Biosystems
1
FeF Chemicals
14
West
2
Want to get involved? Contact Marc Rhys-Evans on
+44(0)20 7827 5945 or marc.rhys-evans@terrapinn.com
10
IT’S A NETWORKING EVENT
“Well organised, interesting sessions, high calibre attendees
supporting good networking opportunities”
Merck
Networking Drinks Reception
It’s not always about the conference sessions.
The Networking Drinks Reception in the evening of day one will allow you to unwind with
your peers and continue conversations in good company.
1-2-1 Partnering
If you come in as a high level sponsor, leading you to the event you will be assigned
your very own Networking Manager who will be at your beck and call to help you set up
meetings in advance of your arrival to the event.
Approximately 4 weeks before the event your dedicated Networking Manager will
contact you to review the delegate list and determine which companies you want to
meet. After gathering this information, your Networking Manager will plan your meeting
schedule. The week of the event you shall receive your meeting schedule.
On site at the event you will report to the “designated” meeting point where your
Networking Manger will introduce you to your perspective business partner and escort
you to a private meeting room or table so you can conduct your meeting.
Your Networking Manager will be at your service before, during and after the event to
make sure you have a great experience at the event and make lots of new contacts.
Scientific Posters
A dedicated Poster Session during the lunch of day one will provide the opportunity to
display previously unpublished research, answer questions and receive feedback on your
work. Posters will be on display for the duration of the event.
The poster should be A0 size (118.9cm x 84.1cm) and printed in portrait orientation. We will
provide materials for mounting. Power sources are not available. (Please note a member of
your organisation must be in attendance at the Congress to be eligible for a poster.)
Networking Lunches
Our extended lunch periods will provide you with ample time to network between
sessions. These lunch formats allow for more opportunities for casual conversations and
introductions, without compromising your time attending the conference sessions.
Solution Provider Exhibition
Explore the exhibition hall during dedicated breaks and meet with solution providers that
offer innovative services and technologies. With over 20 exhibitors, you are sure to meet
those that can help with any challenges you face in your veterinary vaccine work.
Want to get involved? Contact Marc Rhys-Evans on +44(0)20 7827 5945 or marc.rhys-evans@terrapinn.com
11
RESERVE YOUR PLACE TODAY
SPONSORS AND EXHIBITORS
The earlier you book, the more you’ll save.
Sponsors
terrapinn.com/bookvetvacc
PACKAGES
BOOK BEFORE
5 JUNE
Book before
31 July
Book before
21 Aug
Book before
11 Sep
Book before
2 Oct
Full price
Standard Package
€1,235
SAVE 50%
€1,970
SAVE €490
€2,090
SAVE €370
€2,210
SAVE €250
€2,340
SAVE €120
€2,460
€840
SAVE €195
€885
SAVE €150
€930
SAVE €105
€980
SAVE €55
€1,035
€50
€50
€50
€50
€50
Academic & Regulatory
Package
Display a Scientific
Poster
€50
Exhibitors
BOOK NOW
Register at terrapinn.com/bookvetvacc
Or call +44 (0)20 7092 1160
BRING YOUR TEAM
Media Partners
There’s so much great content, you can’t possibly cover it all alone!
Bring your team and get an extra discount.
Call +44 (0)20 7092 1160
Contact Marc Rhys-Evans directly to tailor-make your pre-event and on-site package on +44(0)20 7827 5945 or marc.rhys-evans@terrapinn.com
13